EANS-Adhoc: Dr. Alfred Bach resigns as CEO of SYGNIS Pharma AG
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement.
C.E.O. Interviews
28.10.2010
Ad-hoc
Dr. Alfred Bach resigns as CEO of SYGNIS Pharma AG
Heidelberg, 28 October 2010 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) announced today that the management contract of Dr. Alfred Bach, which is going to expire at the end of the calendar-year, will not be extended upon Dr. Bach´s request. By mutual consent with the Supervisory Board Dr. Bach will resign as CEO of SYGNIS Pharma AG on the end of 28 October 2010.
The Supervisory Board thanks Dr. Bach for his commitment and efforts during the past years for SYGNIS Pharma AG. Peter Willinger, Chief Financial Officer, and, Dr. Frank Rathgeb, Chief Medical Officer, will jointly lead the Company.
For further information please contact:
|Dr. Franz-Werner Haas | |VP Operations / General Counsel | |Tel: +49 (0) 6221-454 812 | |Email: franz-werner.haas@sygnis.de |
end of announcement euro adhoc
Further inquiry note:
Dr. Franz-Werner Haas
VP Operations / General Counsel
Tel: +49 (0) 6221-454 812
Email: franz-werner.haas@sygnis.de
Branche: Biotechnology
ISIN: DE0005043509
WKN: 504350
Index: CDAX, Prime All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade